Voyager Therapeutics, Inc.
Treatment of amyotrophic lateral sclerosis (ALS)
Last updated:
Abstract:
The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).
Status:
Grant
Type:
Utility
Filling date:
16 Oct 2018
Issue date:
6 Sep 2022